Skip to main content
Kane Biotech Inc. logo

Kane Biotech Inc. — Investor Relations & Filings

Ticker · KNE ISIN · CA4838092084 TSXV Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2022-11-30 Regulatory Filings
Country CA Canada
Listing TSXV KNE

About Kane Biotech Inc.

https://kanebiotech.com/

Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of proprietary technologies designed to prevent and remove microbial biofilms, which are a major contributor to chronic infections and impaired healing. The company holds extensive intellectual property related to biofilm formation and dispersal mechanisms, utilizing proprietary technologies such as DispersinB® and coactiv+®. Its primary commercial focus is advanced wound care, where products like the revyve® Antimicrobial Wound Gel and Spray are designed to disrupt biofilms and promote healing. The product pipeline also includes surgical and dermatological applications for both human and animal health.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the Chief Financial Officer of Kane Biotech Inc. regarding the interim financial statements and interim MD&A for the period ended September 30, 2022. It explicitly states it is a 'Venture Issuer Basic Certificate' and focuses on certifying the accuracy and fair presentation of the interim filings. The document does not contain the actual interim financial statements or substantive financial data but is a formal attestation related to those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3023 characters), and it is clearly a certification letter rather than a full report or announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-11-30 English
Interim MD&A - English.pdf
Regulatory Filings
2022-11-30 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of Kane Biotech's third quarter 2022 financial results, including comprehensive financial data such as revenue, gross profit, operating expenses, loss figures, and balance sheet items as of September 30, 2022. It also includes management commentary, recent corporate developments, and an invitation to a conference call to discuss these results. The presence of detailed financial statements and analysis for a quarterly period (three months ended September 30, 2022) indicates this is a comprehensive interim financial report. The document is over 11,000 characters, so it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is an Interim / Quarterly Report (IR).
2022-11-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the submission of a 510(k) premarket notification to the FDA for a new antimicrobial hydrogel product by Kane Biotech. It discusses the product, its technology, and the company's business context. There is no financial data, no regulatory filing of financial reports, no shareholder meeting information, no management changes, no earnings or interim report, no audit or legal proceedings, and no capital or financing update. The document is a corporate announcement about a regulatory submission and product development milestone, typical of a general regulatory announcement or press release. It does not fit into any specific financial or governance report categories. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories. The document length is under 5,000 characters, but it is not announcing the publication of a report, so it is not RPA. Confidence is high due to clear content and context.
2022-11-03 English
Interim MD&A - English.pdf
Regulatory Filings
2022-08-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.